Among these, L-glutamate increases enzyme activity in vitro by three-fold, while efavirenz, an antiretroviral medication, has emerged as a low-dose activator of CYP46A1, suggesting its potential as a novel treatment for AD [36,265,272]. This evidence concerns the gene CYP46A1 and Alzheimer disease.